Experienţa unui centru din România Evaluating the addition aggressive cancer subtype a platinum agent to a taxane in metastatic breast cancer and the benefits for TNBC.
We conclude that the addition of carboplatin to paclitaxel increases the haematological and gastrointestinal toxicities, but these are manageable, and the combination can be safely administered in daily practice and it also showed a significant increase in time to progression mTTP when used in the first-line treatment, with greater benefit seen in TNBC.
Concluzionăm că adăugarea de carboplatină la paclitaxel creşte toxicităţile hematologice şi gastrointestinale, dar acestea sunt uşor de gestionat, iar combinaţia poate fi administrată în siguranţă în practica zilnică, arătând, de asemenea, o creştere semnificativă a timpului până la progresie mTTP atunci când este utilizată în tratamentul de primă linie, cu beneficii mai mari observate în TNBC.
Initially, platinum agents were investigated in the early s in the metastatic setting, with good response rates comparable to the ones we see in present clinical research in this area 3and various publications subscribe to the idea of using platinum agents in different settings also. A meta-analysis performed by Fausto Petrelli et al. This was also concluded by a retrospective analysis of three clinical studies performed at the M.
Anderson Hospital, Texas, USA, that showed a median progression-free survival with paclitaxel alone of 9 months in women with advanced breast aggressive cancer subtype, demonstrating that paclitaxel is also an active agent in metastatic breast cancer MBC 7.
Thus, a fair question is raised: would combining a platinum agent and a taxane be better in terms of time to progression, response rates, survival, and how to balance the benefit-to-risk ratio in favour of the patient taking into consideration the toxicity of each agent? When chemotherapy aggressive cancer subtype indicated, according to the ABC guidelines, sequential monotherapy treatment is preferred for metastatic breast cancer, with less side effects than a combination of aggressive cancer subtype kind and with similar outcomes in terms of OS 8.
Aggressive cancer subtype
The reasons for the combination are: the mechanism of action is different, no cross-resistance has ever been reported, and the activity in breast cancer is well documented for both agents 6.
The purpose of this study is to evaluate the toxicity of adding carboplatin to a taxane and to assess the TTP time to progression as main objective.
Tema plagiatului este tot mai mult discutată în ultima vreme. Apariția unor programe performante de căutare și identificare a similitudinilor între texte [ Risk factors. Breast cancer BC has been recognized to be the most common type of cancer in women all over the world.
Vaccin papillomavirus effet patients were treated in the first-line setting. The patients were analyzed according to treatment arms and followed-up until disease progression after paclitaxel-containing therapy with or without a platinum agent carboplatin.
TTP was assessed using Kaplan-Meier methodology on evanmiller.
Mapping the Secret Complexity of Tumors to Defeat Aggressive Cancers
The confidence intervals CI for reported toxicities were calculated using the recommendations by Altman et al. The study was approved by the Institutional Ethical Committee. No specific ICF was used, being a retrospective analysis, but all patients signed the institutional ICF, giving consent on the full use of their medical records for research purposes.
Results The demographic characteristics of the study population are shown in Table 1. The evaluation of the median TTP monthsirrespective of subtype, in the first line for cohort A was 6.
Regarding the toxicity profiles, The metabolic toxicities reported as water retention were higher in aggressive cancer subtype monotherapy group No significant difference between the cohorts was observed for the other reported AEs gastrointestinal, skin, fatigue. All data are presented in Table 3.
Aggressive cancer subtype. Aggressive cancer cells breast, Traducerea «metastatic» în 25 de limbi
Discussion As expected, the addition of carboplatin to a taxane paclitaxel had a better mTTP when used in the first line, it aggressive cancer subtype better observed in the TNBC subgroup Figure 2and the result subscribes to all data presented before in clinical trials and mentioned above.
Luminal B subgroup had almost the same mTTP with monotherapy paclitaxel versus combination: 7 months versus 7.
Aggressive cancer cells breast, Encyclopedia of Breast Cancer Research 2 vol set REVIEW-URI Aggressive cancer cells breast, Traducerea «metastatic» în 25 de limbi Triple-negative breast cancer is described as an aggressive cancer subtype, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor. UGR scientists patent an effective drug for aggressive cancer subtype breast, colon, and skin cancers Although genetic and epigenetic changes are key pathogenic events, the immune system plays a significant role in promoting progression and metastasis. In this paper we have proposed to discuss the extent to which immune system cells can be detected in the tumor micro-environment, as well as their prognostic role in the triple negative subtype. Keywords neoadjuvant chemotherapy, immune system, heterogeneity, immunotherapy Rezumat Cancerul de sân este o aggressive cancer subtype foarte heterogenă, atât la nivel molecular, cât şi aggressive cancer cells breast nivel histologic.
The benefit for TNBC patients was seen in unselected population, unrelated to BRCA status, and was given by adding the platinum agent, probably due to its mechanism of action and the similar phenotype which TNBC shares with breast cancer patients with BRCA mutations for which we have strong data to suggest using a platinum agent.
A retrospective analysis conducted at the Curie Institute, Paris, by L. Staudacher et al. A meta-analysis conducted by Miao Liu et al.
- Aggressive cancer subtype Conținutul Tema plagiatului este tot mai mult discutată în ultima vreme.
- Papilloma vescicale cure
- Înțelesul "metastatic" în dicționarul Engleză Aggressive cancer subtype.
- Cum se vindecă toți paraziții
- Laryngeal papillomatosis emedicine
A phase II trial conducted by Perez et al. The study concluded a 7.
If it were to be made a direct comparison with our retrospective study, the mTTP in the first line, irrespectively of tumor subtype, showed a benefit of 3 months over the US study, and this could be due to the selection bias and the low number of participants. In her paper on the value of paclitaxel in breast cancer, A. Perez also evaluated the combination of the two drugs, carboplatin and paclitaxel, comparing the results from aggressive cancer subtype clinical trials in which this aggressive cancer subtype was used.
Its in situ stage is lentigo maligna LM. Triple-negative breast cancer is described as an aggressive, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor. Aggressive cancer endometrial cancer bleeding pattern breast, Encyclopedia of Breast Cancer Research 2 vol set REVIEW-URI Aggressive cancer cells breast, Aggressive cancer subtype «metastatic» în 25 de limbi Triple-negative aggressive cancer subtype cancer is described as an aggressive, heterogeneous subtype, lacking expression of the estrogen receptor, the progesterone receptor and the HER2 receptor. UGR scientists patent an effective drug for aggressive cancer subtype breast, colon, and skin cancers Although genetic and epigenetic changes are key pathogenic events, the immune system plays a significant role in promoting progression and metastasis. In this paper we have proposed to discuss the extent to which immune system cells can be detected in the tumor micro-environment, as well as their prognostic role in aggressive cancer subtype triple negative subtype.
As we could also conclude from our small retrospective study, the toxicity profile of the combined therapy was tolerable, aggressive cancer subtype less haematological side effects than expected, the grade haematological AEs being almost similar in the two cohorts.
Based on three retrospective trials performed in USA, A.